Verge Genomics rebranded as Verge Labs after it reported disappointing results from an early-stage clinical trial of VRG50635, an AI-designed ALS therapy targeting PIKfyve. The company said the drug failed to produce the intended patient benefit, prompting a major strategic course correction. CEO and founder Alice Zhang said Verge’s platform will shift from building programs in-house to supplying drug developers with target and dataset outputs. The new model emphasizes monetizing datasets and insights derived from prior clinical work, paired with partner-driven target selection and biomarker efforts. The retrenchment highlights the practical constraints of translating AI-designed hypotheses into measurable pharmacology and clinical endpoints, particularly in neurodegeneration where target engagement and downstream biology can be difficult to validate quickly. The rebrand also signals a pivot toward neuroscience partnerships while Verge works to iteratively improve its learning loop using new clinical and translational feedback.